Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Primary Sclerosing Cholangitis After Liver Transplant With Oral Vancomycin (PROP-LT)

13. listopadu 2026 aktualizováno: Yael R. Nobel

Preventing Recurrence of Primary Sclerosing Cholangitis After Liver Transplant (PROP-LT): a Phase 1, Open-label, Controlled Study of Oral Vancomycin

Primary Objective:

  • To evaluate safety of a 4-week course of oral vancomycin (250 mg 3 times daily [TID]) in liver transplant recipients who were transplanted for Primary Sclerosing Cholangitis (PSC).

Secondary Objectives:

  • To determine tolerability and adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC.
  • To assess vancomycin resistant enterococcus (VRE) colonization status over time.
  • To assess the impact of oral vancomycin on stool microbiome composition, diversity, and function.
  • To assess impact of oral vancomycin on microbial metabolite concentrations in blood and stool.
  • To assess impact of oral vancomycin on liver-related biochemical markers.

Přehled studie

Postavení

Zatím nenabíráme

Podmínky

Intervence / Léčba

Detailní popis

Primary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic liver disease characterized by inflammation and fibrosis of the intrahepatic and extrahepatic bile ducts, often associated with inflammatory bowel disease (IBD). A subset of patients ultimately require liver transplantation, yet rPSC occurs in approximately 25-30% of transplant recipients and can lead to graft failure and re-transplantation.

There is increasing evidence that the gut microbiome plays a role in PSC and rPSC pathogenesis. Altered microbiota composition has been identified in patients with PSC. This association is true not only in patients with PSC compared to controls, but also in patients with PSC-IBD compared to patients with IBD-no PSC, indicating a true association with the liver disease itself. Compared to patients with PSC who do not develop post-transplant recurrence, patients who will develop rPSC have altered microbiome composition at the time of liver transplant. Microbial manipulation-including oral antibiotics, fecal microbiota transplantation, and other strategies-has emerged as a potential therapeutic avenue in native liver PSC. In particular, there is mounting interest in oral vancomycin (OV) as a treatment for PSC, as several case reports/case series and a few small trials have demonstrated that OV is associated with reductions in alkaline phosphatase and other markers of liver injury. This effect may be mediated by the impact of OV on bile acid metabolism, short-chain fatty acid production, and/or prevalence of specific bacterial taxa such as Enterococcus gallinarum, a vancomycin-sensitive microbe that has been associated with PSC.

In case reports of patients with post-transplant rPSC, use of OV was also associated with improvement in biochemical markers of liver disease activity. Liver transplant recipients represent a specialized population with unique medication exposures and microbiome composition. While short course of OV are safely used in liver transplant recipients for the treatment of Clostridioides difficile, no prospective study has systematically examined safety, tolerability, microbiome changes, and hepatic effects of OV in liver transplant recipients transplanted for PSC.

Typ studie

Intervenční

Zápis (Odhadovaný)

21

Fáze

  • Fáze 1

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

Studijní záloha kontaktů

Studijní místa

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  • Age ≥ 18 years

  • Ability to provide written, informed consent.

  • History of orthotopic liver transplantation within 1 to 10 years prior to enrollment (i.e. study drug initiation)

  • Diagnosis of PSC as the underlying liver disease leading to liver transplantation, based on compatible imaging findings (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], percutaneous transhepatic cholangiogram [PTC]), liver histology, and/or clinician judgment

  • Subjects with or without IBD may be enrolled. IBD diagnosis with a minimum disease duration of 6 months as assessed by endoscopy/histology. IBD should be in clinical remission or mildly active according to accepted clinical scores and/or clinician judgment.

  • Stable liver graft function, as determined by ALL of the following criteria:

    • No episodes of acute rejection within 6 months prior to enrollment, based on liver histology and/or clinical signs or symptoms
    • No episodes of cholangitis within 6 months prior to study enrollment, based on positive bacterial cultures, compatible imaging, and/or clinical signs or symptoms
    • No intervention for biliary obstruction (e.g. ERCP, PTC, surgical intervention) within 6 months prior to study enrollment.
    • Stable liver biochemistries within 6 months prior to study enrollment, as determined by: ALP <5x ULN
    • Absence of histologic or imaging findings suggestive of cirrhosis

Exclusion Criteria:

  • History of colon resection at any time prior to study enrollment or presence of ileal/colonic diversion within 12 months prior to study enrollment
  • Documented VRE infection within 12 months prior to study enrollment
  • Documented C. difficile infection within 3 months prior to study enrollment
  • Systemic antibiotic exposure within 3 months prior to study enrollment
  • Change in any transplant or IBD-related immunosuppression or its dosing within 30 days prior to study enrollment
  • Currently taking oral vancomycin
  • Allergy or intolerance to vancomycin
  • Treatment with any investigational drug within 3 months prior to study enrollment
  • Severe renal dysfunction (eGFR <30 mL/min/1.73 m²) or on dialysis
  • Any active malignancy
  • Pregnant or breastfeeding Page 8
  • Any condition that, in the investigator's judgment, would make participation unsafe or interfere with adherence (e.g., severe frailty, uncontrolled psychiatric disease, inability to adhere to TID dosing)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Nerandomizované
  • Intervenční model: Sekvenční přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Study Arm - Oral Vancomycin

Patients in study arm will be assigned to receive study drug.

Vancomycin 250 mg orally three times per day (TID, 750 mg/day), with doses spaced approximately 8 hours apart (e.g., morning, midday, evening), for a total duration of 4 weeks. Missed doses will not be made up; participants will be instructed to resume the next scheduled dose.

Vancomycin is a glycopeptide antibiotic supplied as oral capsules 250 mg. It acts by inhibiting bacterial cell wall synthesis. Oral vancomycin is minimally absorbed in patients with intact gut mucosa, resulting in high intraluminal concentrations.

Ostatní jména:
  • VANCOCIN®
  • vancomycin hydrochloride
Žádný zásah: Control Arm - No Drug

Patients in control arm will be assigned to receive no drug.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of patients experiencing any treatment-related adverse event of grade ≥2
Časové okno: Up to 4 weeks

This is to evaluate safety of a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The assessments will be using CTCAE v6.0 grading in the study arm receiving vancomycin compared to the control arm. Percentage (or the number) of study participants who experience related AEs of grade > or = 2 will be tallied and calculated.

Up to 4 weeks

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Change in patient-reported short form-36 symptom questionnaire score
Časové okno: Baseline to 4 weeks, baseline to 8 weeks

To determine tolerability to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The clinical outcomes will be recorded using the SF-36 questionnaire. SF-36 is a set of generic, coherent, and easily administered quality-of-life measures. Items are scored 0-100 with higher scores indicating a more favorable health state.

Baseline to 4 weeks, baseline to 8 weeks
Proportion of participants who complete 4 weeks of oral vancomycin with ≥ 80% of planned doses
Časové okno: Up to 4 weeks

To determine adherence to a 4-week course of oral vancomycin (250 mg TID) in liver transplant recipients who were transplanted for PSC. The completion of study treatment will be defined, assessed and tallied by self-report and/or pill count.

Up to 4 weeks
Proportion of participants with VRE Colonization Status
Časové okno: Baseline, Week 4, and Week 8

The status will be determined by the presence or absence of vancomycin-resistant Enterococcus (VRE) colonization based on stool sample or rectal swab testing. The result will be positive or negative. The participants with positive results will be tallied.

Baseline, Week 4, and Week 8
Proportion of participants with changes in Stool Microbiome Composition and Diversity
Časové okno: Baseline to 4 weeks, Baseline to 8 weeks

Proportion of participants with change in microbiome composition from baseline to subsequent timepoints as assessed by alpha and beta diversity, differential taxa abundance, and/or changes in genes and gene pathways.

Baseline to 4 weeks, Baseline to 8 weeks
Proportion of participants with change in liver-related biochemical markers
Časové okno: Baseline and 4 weeks, Baseline and 8 weeks

Participants with change in ALP, ALT, and/or GGT (particularly a decrease in ALP) will be tallied and calculated.

Baseline and 4 weeks, Baseline and 8 weeks
Proportion of participants with change in microbial metabolite concentrations.
Časové okno: Baseline and 4 weeks, Baseline and 8 weeks

Participants with changes in microbial metabolite such as short chain fatty acids and bile acids will be tallied and calculated.

Baseline and 4 weeks, Baseline and 8 weeks

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

Vyšetřovatelé

  • Vrchní vyšetřovatel: Yael R Nobel, M.D., M.S., Assistant Professor of Medicine Center for Liver Disease and Transplantation

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. listopadu 2026

Primární dokončení (Odhadovaný)

1. listopadu 2027

Dokončení studie (Odhadovaný)

1. listopadu 2030

Termíny zápisu do studia

První předloženo

13. listopadu 2026

První předloženo, které splnilo kritéria kontroly kvality

13. listopadu 2026

První zveřejněno (Aktuální)

18. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

18. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

13. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • ACYY2503

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .